Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 52% by 2026.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 493.28 for the 2024 fiscal year.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company sustains low margins.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.
Over the past four months, analysts' average price target has been revised downwards significantly.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.